Anaesthetic Management of a Patient With Immune-Mediated Necrotizing Muscle Disease With the Use of a Novel Ultrashort-Acting Benzodiazepine, Remimazolam: A Case Report

We reported the anesthetic management of remimazolam, a novel ultra-short-acting benzodiazepine, for a 21-month-old female with immune-mediated necrotizing myopathy (IMNM). Remimazolam has a similar chemical structure to midazolam but possesses a unique side chain that reduces its propensity to accu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogino, Hitoshi, Sugiyama, Daisuke, Ueda, Kenichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Anesthesiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168013/
https://www.ncbi.nlm.nih.gov/pubmed/37182089
http://dx.doi.org/10.7759/cureus.37326
_version_ 1785038779409498112
author Ogino, Hitoshi
Sugiyama, Daisuke
Ueda, Kenichi
author_facet Ogino, Hitoshi
Sugiyama, Daisuke
Ueda, Kenichi
author_sort Ogino, Hitoshi
collection PubMed
description We reported the anesthetic management of remimazolam, a novel ultra-short-acting benzodiazepine, for a 21-month-old female with immune-mediated necrotizing myopathy (IMNM). Remimazolam has a similar chemical structure to midazolam but possesses a unique side chain that reduces its propensity to accumulate in the body, thereby minimizing prolonged sedation or respiratory depression. Our experience supports that remimazolam could be a suitable agent for anesthetizing the patient with IMNM.
format Online
Article
Text
id pubmed-10168013
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-101680132023-05-10 Anaesthetic Management of a Patient With Immune-Mediated Necrotizing Muscle Disease With the Use of a Novel Ultrashort-Acting Benzodiazepine, Remimazolam: A Case Report Ogino, Hitoshi Sugiyama, Daisuke Ueda, Kenichi Cureus Anesthesiology We reported the anesthetic management of remimazolam, a novel ultra-short-acting benzodiazepine, for a 21-month-old female with immune-mediated necrotizing myopathy (IMNM). Remimazolam has a similar chemical structure to midazolam but possesses a unique side chain that reduces its propensity to accumulate in the body, thereby minimizing prolonged sedation or respiratory depression. Our experience supports that remimazolam could be a suitable agent for anesthetizing the patient with IMNM. Cureus 2023-04-09 /pmc/articles/PMC10168013/ /pubmed/37182089 http://dx.doi.org/10.7759/cureus.37326 Text en Copyright © 2023, Ogino et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Anesthesiology
Ogino, Hitoshi
Sugiyama, Daisuke
Ueda, Kenichi
Anaesthetic Management of a Patient With Immune-Mediated Necrotizing Muscle Disease With the Use of a Novel Ultrashort-Acting Benzodiazepine, Remimazolam: A Case Report
title Anaesthetic Management of a Patient With Immune-Mediated Necrotizing Muscle Disease With the Use of a Novel Ultrashort-Acting Benzodiazepine, Remimazolam: A Case Report
title_full Anaesthetic Management of a Patient With Immune-Mediated Necrotizing Muscle Disease With the Use of a Novel Ultrashort-Acting Benzodiazepine, Remimazolam: A Case Report
title_fullStr Anaesthetic Management of a Patient With Immune-Mediated Necrotizing Muscle Disease With the Use of a Novel Ultrashort-Acting Benzodiazepine, Remimazolam: A Case Report
title_full_unstemmed Anaesthetic Management of a Patient With Immune-Mediated Necrotizing Muscle Disease With the Use of a Novel Ultrashort-Acting Benzodiazepine, Remimazolam: A Case Report
title_short Anaesthetic Management of a Patient With Immune-Mediated Necrotizing Muscle Disease With the Use of a Novel Ultrashort-Acting Benzodiazepine, Remimazolam: A Case Report
title_sort anaesthetic management of a patient with immune-mediated necrotizing muscle disease with the use of a novel ultrashort-acting benzodiazepine, remimazolam: a case report
topic Anesthesiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168013/
https://www.ncbi.nlm.nih.gov/pubmed/37182089
http://dx.doi.org/10.7759/cureus.37326
work_keys_str_mv AT oginohitoshi anaestheticmanagementofapatientwithimmunemediatednecrotizingmusclediseasewiththeuseofanovelultrashortactingbenzodiazepineremimazolamacasereport
AT sugiyamadaisuke anaestheticmanagementofapatientwithimmunemediatednecrotizingmusclediseasewiththeuseofanovelultrashortactingbenzodiazepineremimazolamacasereport
AT uedakenichi anaestheticmanagementofapatientwithimmunemediatednecrotizingmusclediseasewiththeuseofanovelultrashortactingbenzodiazepineremimazolamacasereport

Ejemplares similares